Deep Brain Stimulation Devices Market Size, Share, Growth Analysis, By Product Type(Rechargeable DBS devices, non-rechargeable DBS devices), By Application(Parkinson's disease, essential tremor), By End-user(Hospitals, ambulatory surgical centers) - Industry Forecast 2024-2031

Deep Brain Stimulation Devices Market size was valued at USD 1.02 billion in 2021 and is poised to grow from USD 1.41 billion in 2022 to USD 2.87 billion by 2030, at a CAGR of 9.29% during the forecast period (2023-2030).

The competitive landscape of the deep brain stimulation devices market is characterized by the presence of several key players striving to gain a significant market share. These players are focused on strategies such as product development, collaborations, mergers and acquisitions, and geographic expansions to strengthen their market position. Major companies in the market are investing heavily in research and development activities to introduce technologically advanced and innovative deep brain stimulation devices. They are also engaged in strategic partnerships with healthcare institutions and research organizations to enhance their product portfolios and expand their geographic reach. 'Medtronic plc (Ireland)', 'Boston Scientific Corporation (US)', 'Abbott Laboratories (US)', 'LivaNova PLC (UK)', 'Sapiens Neuro (US)', 'Beijing PINS Medical Co., Ltd. (China)', 'SceneRay Corporation (China)', 'Nevro Corp. (US)', 'Aleva Neurotherapeutics SA (Switzerland)', 'Functional Neuromodulation Ltd. (Canada)', 'NeuroPace, Inc. (US)', 'Neuronetics, Inc. (US)', 'Brainsway Ltd. (Israel)', 'Synaptive Medical Inc. (Canada)', 'Alpha Omega Engineering Ltd. (Israel)', 'Nexeon MedSystems, Inc. (US)', 'Autonomix Medical, Inc. (US)', 'Greatbatch Medical (US)', 'SceneRay Corp. (China)', 'Saluda Medical Pty Ltd. (Australia)'

Innovations in deep brain stimulation technology have significantly improved patient outcomes, expanded the range of treatable conditions, and enhanced the overall efficacy and safety of the therapy. Technological advancements include the development of more precise targeting systems, improved stimulation parameters, and the integration of advanced features such as closed-loop systems and adaptive algorithms. These advancements enable personalized treatment approaches, better symptom management, and reduced side effects.

Increasing prevalence of neurological disorders is driving the demand: Deep brain stimulation (DBS) is a surgical procedure that uses electrical stimulation to treat a variety of neurological disorders, including Parkinson's disease, essential tremor, and dystonia. This increase in prevalence is due to a number of factors, including the aging population, the rise in chronic diseases, and the increasing environmental toxins. The increasing prevalence of neurological disorders is driving the demand for DBS devices, as they are a highly effective treatment for many of these disorders.

The largest market region is North America. North America holds a significant share in the market due to several key factors. The region has a well-established healthcare infrastructure with advanced medical facilities and expertise in neurology. This infrastructure enables efficient diagnosis and treatment of neurological disorders, leading to a higher demand for deep brain stimulation devices. North America has a high prevalence of neurological disorders, particularly Parkinson's disease, which drives the need for effective treatment options such as deep brain stimulation. Additionally, favorable reimbursement policies and strong healthcare expenditure further support the growth of the deep brain stimulation devices market in the region.

Deep Brain Stimulation Devices Market size was valued at USD 1.02 billion in 2021 and is poised to grow from USD 1.41 billion in 2022 to USD 2.87 billion by 2030, at a CAGR of 9.29% during the forecast period (2023-2030).

The competitive landscape of the deep brain stimulation devices market is characterized by the presence of several key players striving to gain a significant market share. These players are focused on strategies such as product development, collaborations, mergers and acquisitions, and geographic expansions to strengthen their market position. Major companies in the market are investing heavily in research and development activities to introduce technologically advanced and innovative deep brain stimulation devices. They are also engaged in strategic partnerships with healthcare institutions and research organizations to enhance their product portfolios and expand their geographic reach. 'Medtronic plc (Ireland)', 'Boston Scientific Corporation (US)', 'Abbott Laboratories (US)', 'LivaNova PLC (UK)', 'Sapiens Neuro (US)', 'Beijing PINS Medical Co., Ltd. (China)', 'SceneRay Corporation (China)', 'Nevro Corp. (US)', 'Aleva Neurotherapeutics SA (Switzerland)', 'Functional Neuromodulation Ltd. (Canada)', 'NeuroPace, Inc. (US)', 'Neuronetics, Inc. (US)', 'Brainsway Ltd. (Israel)', 'Synaptive Medical Inc. (Canada)', 'Alpha Omega Engineering Ltd. (Israel)', 'Nexeon MedSystems, Inc. (US)', 'Autonomix Medical, Inc. (US)', 'Greatbatch Medical (US)', 'SceneRay Corp. (China)', 'Saluda Medical Pty Ltd. (Australia)'

Innovations in deep brain stimulation technology have significantly improved patient outcomes, expanded the range of treatable conditions, and enhanced the overall efficacy and safety of the therapy. Technological advancements include the development of more precise targeting systems, improved stimulation parameters, and the integration of advanced features such as closed-loop systems and adaptive algorithms. These advancements enable personalized treatment approaches, better symptom management, and reduced side effects.

Increasing prevalence of neurological disorders is driving the demand: Deep brain stimulation (DBS) is a surgical procedure that uses electrical stimulation to treat a variety of neurological disorders, including Parkinson's disease, essential tremor, and dystonia. This increase in prevalence is due to a number of factors, including the aging population, the rise in chronic diseases, and the increasing environmental toxins. The increasing prevalence of neurological disorders is driving the demand for DBS devices, as they are a highly effective treatment for many of these disorders.

The largest market region is North America. North America holds a significant share in the market due to several key factors. The region has a well-established healthcare infrastructure with advanced medical facilities and expertise in neurology. This infrastructure enables efficient diagnosis and treatment of neurological disorders, leading to a higher demand for deep brain stimulation devices. North America has a high prevalence of neurological disorders, particularly Parkinson's disease, which drives the need for effective treatment options such as deep brain stimulation. Additionally, favorable reimbursement policies and strong healthcare expenditure further support the growth of the deep brain stimulation devices market in the region.

Deep Brain Stimulation Devices Market size was valued at USD 1.41 billion in 2022 and is poised to grow from USD 1.54 billion in 2023 to USD 3.14 billion by 2031, at a CAGR of 9.29% during the forecast period (2024-2031).

The competitive landscape of the deep brain stimulation devices market is characterized by the presence of several key players striving to gain a significant market share. These players are focused on strategies such as product development, collaborations, mergers and acquisitions, and geographic expansions to strengthen their market position. Major companies in the market are investing heavily in research and development activities to introduce technologically advanced and innovative deep brain stimulation devices. They are also engaged in strategic partnerships with healthcare institutions and research organizations to enhance their product portfolios and expand their geographic reach. 'Medtronic plc (Ireland)', 'Boston Scientific Corporation (US)', 'Abbott Laboratories (US)', 'LivaNova PLC (UK)', 'Sapiens Neuro (US)', 'Beijing PINS Medical Co., Ltd. (China)', 'SceneRay Corporation (China)', 'Nevro Corp. (US)', 'Aleva Neurotherapeutics SA (Switzerland)', 'Functional Neuromodulation Ltd. (Canada)', 'NeuroPace, Inc. (US)', 'Neuronetics, Inc. (US)', 'Brainsway Ltd. (Israel)', 'Synaptive Medical Inc. (Canada)', 'Alpha Omega Engineering Ltd. (Israel)', 'Nexeon MedSystems, Inc. (US)', 'Autonomix Medical, Inc. (US)', 'Greatbatch Medical (US)', 'SceneRay Corp. (China)', 'Saluda Medical Pty Ltd. (Australia)'

Innovations in deep brain stimulation technology have significantly improved patient outcomes, expanded the range of treatable conditions, and enhanced the overall efficacy and safety of the therapy. Technological advancements include the development of more precise targeting systems, improved stimulation parameters, and the integration of advanced features such as closed-loop systems and adaptive algorithms. These advancements enable personalized treatment approaches, better symptom management, and reduced side effects.

Increasing prevalence of neurological disorders is driving the demand: Deep brain stimulation (DBS) is a surgical procedure that uses electrical stimulation to treat a variety of neurological disorders, including Parkinson's disease, essential tremor, and dystonia. This increase in prevalence is due to a number of factors, including the aging population, the rise in chronic diseases, and the increasing environmental toxins. The increasing prevalence of neurological disorders is driving the demand for DBS devices, as they are a highly effective treatment for many of these disorders.

The largest market region is North America. North America holds a significant share in the market due to several key factors. The region has a well-established healthcare infrastructure with advanced medical facilities and expertise in neurology. This infrastructure enables efficient diagnosis and treatment of neurological disorders, leading to a higher demand for deep brain stimulation devices. North America has a high prevalence of neurological disorders, particularly Parkinson's disease, which drives the need for effective treatment options such as deep brain stimulation. Additionally, favorable reimbursement policies and strong healthcare expenditure further support the growth of the deep brain stimulation devices market in the region.